Core Insights - HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing fusion immunotherapeutics for chronic inflammation-related diseases, including autoimmune disorders and cancer [1][18] - The company reported financial results for the three months ended December 31, 2025, highlighting a significant decrease in revenues and a net gain for the quarter [11][15] Clinical Development - The company initiated its first-in-human clinical trial for HCW9302, targeting alopecia areata, with a focus on evaluating safety and determining recommended dose levels [2][4] - HCW9302 is designed to activate and expand regulatory T cells to suppress auto-reactive immune cells, addressing a condition that affects approximately 160 million people globally [3][4] - Preliminary human data readout from the Phase 1 study is expected in the first half of 2026 [4] Business Highlights - HCW Biologics received a $3.5 million upfront licensing fee for HCW11-006, licensed to Beijing Trimmune Biotech Co., Ltd., with potential for additional milestone payments and royalties [6][7] - The company launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics, aiming to generate revenue to offset development costs [9] Financial Performance - Revenues for Q4 2025 were $27,010, a significant drop from $394,804 in Q4 2024, with total revenues for the year decreasing from $2.6 million to $54,232 [11] - Research and development expenses increased by 27% in Q4 2025 compared to Q4 2024, while total R&D expenses for the year decreased by 15% [12] - General and administrative expenses decreased by 26% in Q4 2025, but increased by 13% for the full year [13] - The company reported a net gain of $2.2 million for Q4 2025, compared to a net loss of $3.4 million in Q4 2024, and a reduced net loss for the year from $30 million to $6.5 million [15] Financial Guidance - As of December 31, 2025, the company expressed substantial doubt regarding its ability to continue as a going concern without additional funding [16] - The company regained compliance with Nasdaq listing rules but faces ongoing monitoring and potential delisting risks due to stock price fluctuations [17]

Core Insights - Zenas BioPharma is preparing to submit marketing applications for obexelimab for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, following positive Phase 3 INDIGO trial results [1][4] - The company anticipates topline results from the Phase 2 SunStone trial for systemic lupus erythematosus (SLE) in Q4 2026 [1][4] - Zenas has secured up to $250 million in non-dilutive debt financing from Pharmakon, enhancing its financial flexibility for commercialization and pipeline investments [1][6] Corporate Highlights - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, showing a 56% reduction in IgG4-RD flare risk compared to placebo in the INDIGO trial [4][12] - The company is advancing multiple pipeline programs, including orelabrutinib for multiple sclerosis (MS) and ZB021, an oral IL-17AA/AF inhibitor, with Phase 1 trials expected to start in Q2 2026 [2][3][7] - ZB014, a new half-life extended anti-CD-19 and FcγRIIb antibody, is also progressing toward clinical development [3][4] Financial Results - For the year ended December 31, 2025, Zenas reported revenue of $10 million, primarily from a license agreement, compared to $5 million in 2024 [10][11] - Research and development expenses increased to $168.1 million in 2025 from $139.1 million in 2024, driven by higher personnel and clinical trial costs [13][21] - The net loss for the year was $377.7 million, compared to a net loss of $157.0 million in 2024 [13][21] Balance Sheet - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $360.5 million, up from $350.8 million in 2024 [22] - Total liabilities increased to $141.5 million from $57.5 million in 2024, reflecting the new debt facility [22] - The accumulated deficit reached $765.1 million as of December 31, 2025, compared to $387.4 million in 2024 [22]

Core Insights - Nektar Therapeutics has announced a research collaboration with UCSF and Dr. Stephen Hauser to explore NKTR-0165, a TNFR2 antibody, for treating multiple sclerosis [1] - The collaboration aims to investigate TNFR2 agonism's potential in reducing neurodegeneration and promoting neuroprotection in multiple sclerosis models [1] - NKTR-0165 is currently in IND-enabling studies and is being developed for various autoimmune and CNS disorders, including multiple sclerosis [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [1] - The company's lead product candidate, rezpegaldesleukin (NKTR-358), is being evaluated in Phase 2b clinical trials for atopic dermatitis and alopecia areata, as well as in a Phase 2 trial for Type 1 diabetes [1] - Nektar's pipeline includes NKTR-0165, NKTR-0166, and NKTR-422, among others, targeting various autoimmune and CNS disorders [1] Research Collaboration Details - The collaboration with UCSF will be led by Dr. Hauser and his team, who will conduct and fund the research while Nektar supplies NKTR-0165 [1] - Dr. Hauser's previous work has significantly impacted multiple sclerosis treatment, leading to new FDA-approved therapies [1] - The research will evaluate the neuroprotective effects of TNFR2 agonism in treating multiple sclerosis and other neurological conditions [1] Multiple Sclerosis Context - Multiple sclerosis is a chronic autoimmune disease affecting approximately 2.9 million people globally and 1 million in the U.S., characterized by the immune system attacking the myelin sheath of nerve fibers [1] - The disease disrupts communication within the central nervous system, leading to symptoms such as muscle weakness, vision loss, and cognitive decline [1]

February 11, 2026 Nasdaq Ticker: ZURA Forward-looking statements disclaimer Corporate overview Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio's expectations regarding its product candidates and their related benefits, and Zura Bio's beliefs regarding competing product candidates and products both in development and ...

Core Insights - Priovant Therapeutics announced positive results from the Phase 2 BEACON study for brepocitinib in cutaneous sarcoidosis, marking a significant milestone in the treatment of this neglected disease [1][2] Company Overview - Priovant Therapeutics is focused on developing novel therapies for autoimmune diseases with high morbidity and limited treatment options [10] - The lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1, targeting key cytokines linked to autoimmunity [10] - The company plans to initiate a Phase 3 program for cutaneous sarcoidosis in 2026, following engagement with the FDA [7][10] Study Details - The BEACON study enrolled 31 patients across 15 sites in the U.S., with a randomized design comparing brepocitinib 45 mg, 15 mg, and placebo over a 16-week treatment period [2][5] - The 45 mg treatment group included patients with longstanding and difficult-to-treat disease, yet achieved significant clinical improvements compared to placebo [2][5] Efficacy Results - Brepocitinib 45 mg achieved a 22.3-point mean improvement in the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity score (CSAMI-A) at Week 16, compared to a 0.7-point improvement in placebo (Δ 21.6, P<0.0001) [3][5] - 100% of patients in the 45 mg group achieved at least a 10-point improvement on CSAMI-A, while 62% reached functional remission (CSAMI-A <5) [4][5] Patient Outcomes - On the Investigator's Global Assessment (IGA), 69% of brepocitinib 45 mg patients achieved a two-point improvement to "Clear" or "Almost Clear," compared to 0% in the placebo group (Δ 69%, P=.0047) [5][6] - Brepocitinib also showed significant improvements in key patient-reported outcomes, with 100% of 45 mg patients reporting improvement on the Patient's Global Impression of Change (PGI-C) [6] Safety Profile - Brepocitinib was well tolerated, with no serious adverse events reported and all adverse events classified as mild or moderate [7] - The safety profile aligns with that of other approved JAK1 and TYK2 inhibitors, having been evaluated in over 1,500 patients [7]

Core Insights - Zenas BioPharma's phase III INDIGO study for obexelimab in treating IgG4-related disease has met its primary endpoint, showing a significant reduction in flare risk [1][2][7] Study Results - Obexelimab demonstrated a 56% reduction in the risk of IgG4-RD flare compared to placebo over a 52-week period, achieving the primary endpoint of the INDIGO study [2][7] - The treatment also showed significant efficacy across four key secondary endpoints, including reductions in investigator-assessed flares and the number of flares requiring rescue therapy [3][7] Market Reaction - Despite the positive study results, Zenas BioPharma's shares fell by 51.9% on January 5, indicating that the efficacy data may not have met investor expectations [4][7] Future Plans - The company plans to submit a biologics license application to the FDA for obexelimab in Q2 2026 and a marketing authorization application to the European Medicines Agency in the second half of 2026 [5][7] Ongoing Development - Zenas BioPharma is also exploring obexelimab for other autoimmune diseases, with ongoing studies for systemic lupus erythematosus and multiple sclerosis [8][9] - The company is focused on the successful development of obexelimab and other pipeline candidates, as it currently lacks a marketed product [10] Stock Performance - Over the past six months, Zenas BioPharma's shares have increased by 69.7%, outperforming the industry average rise of 21.5% [6]

Core Insights - Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab, showing a 56% reduction in the risk of IgG4-RD flare compared to placebo, with a Hazard Ratio of 0.44 and p=0.0005 [1][2] - Obexelimab demonstrated statistically significant activity on all four key secondary efficacy endpoints, including reduction in flares requiring rescue therapy and the proportion of patients achieving complete remission [1][2] - The company plans to submit a Biologics License Application (BLA) to the FDA in Q2 2026 and a Marketing Authorization Application (MAA) to the EMA in H2 2026 [1][2] Company Overview - Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune diseases [15] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting IgG4-RD [15] - Zenas aims to address the unmet medical needs of patients with autoimmune diseases through innovative therapies [15] Clinical Trial Details - The Phase 3 INDIGO trial enrolled 194 patients and was designed to evaluate the safety and efficacy of obexelimab over a 52-week period [10] - The primary endpoint was the time to first IgG4-RD flare requiring rescue therapy, with key secondary endpoints including the number of flares and the cumulative use of rescue therapy [11][12] - Obexelimab was well tolerated, with lower rates of infections and similar incidence of injection site reactions compared to placebo [1][2] Future Developments - Zenas expects to report topline results from the Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) in Q4 2026 [4] - The company is also studying orelabrutinib in a global Phase 3 trial for Primary Progressive Multiple Sclerosis (PPMS) and plans to initiate a trial for non-active Secondary Progressive Multiple Sclerosis (naSPMS) in Q1 2026 [4] - Zenas is preparing to initiate Phase 1 clinical development for two additional product candidates, ZB021 and ZB022, in 2026 [4]

Summary of Biogen's Immunology Pipeline Discussion Company Overview - **Company**: Biogen - **Focus**: Immunology pipeline, particularly the development of felzartamab, a CD38-directed treatment Key Points and Arguments Immunology Pipeline and CD38 Target - Biogen's immunology pipeline is centered around felzartamab, which targets CD38, a molecule implicated in various autoimmune diseases driven by pathogenic antibodies [2][3] - The therapy aims to selectively target plasma cells and plasma blasts, which are responsible for producing these pathogenic antibodies, allowing for more effective treatment options [2] Clinical Focus on Renal Diseases - The primary clinical focus is on late antibody-mediated rejection (AMR) in renal transplantation patients, a significant unmet medical need affecting approximately 11,000 individuals out of 300,000 to 400,000 kidney transplant recipients [8][10] - Late AMR is the leading cause of graft loss, and current therapies are ineffective, highlighting the importance of developing new treatments [8][10] Phase 2 Study Results - A small Phase 2 study with 22 participants showed that two-thirds of patients in the felzartamab group achieved microvascular inflammation (MVI) scores of zero at six months, indicating a significant reduction in inflammation [11] - The study demonstrated an 80% reversal of microvascular inflammation at the six-month mark, which is unprecedented compared to other therapies [11] Phase 3 Study Design - The upcoming Phase 3 study will include a one-year duration with participants randomized to receive either felzartamab or placebo, with a crossover design for placebo participants after six months [12][15] - The primary endpoint will focus on the reversal of AMR by histology, with additional supportive data on graft injury biomarkers and kidney function [16] IgA Nephropathy and Competitive Landscape - In the IgA nephropathy space, felzartamab is positioned as a potential option for durable disease control without the need for ongoing treatment, unlike other therapies that require continuous dosing [21][25] - The market for IgA nephropathy is competitive, but felzartamab's unique mechanism targeting plasma cells may provide a distinct advantage [21][25] PMN Patient Subgroups - In the context of primary membranous nephropathy (PMN), felzartamab may benefit high-risk patients who do not respond to anti-CD20 therapies, as these patients often have plasma cells that do not express CD20 [27][30] - Approximately 30%-50% of PMN patients may not respond to CD20 therapies, indicating a significant opportunity for targeted treatment with felzartamab [30] Future Development Plans - Biogen plans to initiate a Phase 1b study for lupus nephritis and a Phase 2 study for DSA negative AMR, recognizing the importance of these populations in the broader context of autoimmune diseases [32][33] - The company is also exploring additional autoantibody-driven diseases for potential future studies [35] Lupus Development Focus - Biogen is prioritizing systemic lupus erythematosus (SLE) due to its heterogeneous nature and the limited number of approved therapies, with only two currently available [37] - The company is developing two therapies targeting different mechanisms, with promising Phase 2 data and ongoing Phase 3 trials [38][39] Regulatory Considerations - Biogen has established a strong partnership with the FDA to align on endpoints and study designs across its lupus programs, ensuring a robust approach to clinical development [41] Additional Important Insights - The discussion highlighted the evolving landscape of autoimmune disease therapies and the importance of targeted treatments that address the underlying mechanisms of disease [2][21] - The potential for felzartamab to provide durable treatment effects without the need for ongoing dosing is a significant differentiator in the competitive market [25][30]

Hangzhou Highlightll Pharmaceutical Co., Ltd. 杭州高光製藥股份有限公司 (A joint stock company established in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is s ...

Summary of AnaptysBio Conference Call Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Focus**: Development of biologics or antibodies for autoimmune diseases - **Clinical Programs**: Three clinical stage programs including Rosnilimab, AMV033, and AMV101 [1][2] Key Clinical Programs Rosnilimab - **Type**: Selective and potent depleter of pathogenic T cells - **Recent Development**: Positive phase 2b trial readout in arthritis with plans to advance into phase 3 trials for rheumatoid arthritis (RA) [1][24] - **Trial Details**: Robust study with 424 patients, showing high tolerability and sustained responses off-drug [24][30] AMV033 - **Type**: CD122 antagonist blocking IL-15 and IL-2 signaling - **Current Status**: Phase 1b trial initiated for celiac disease, with plans for a second indication in 2026 [1][2][7] - **Mechanism**: Designed to target autoimmune cells, particularly CD8 T cells in diseases like celiac disease and eosinophilic esophagitis (EOE) [8][20] AMV101 - **Current Status**: In phase 1a trials with results expected next year [1][32] Royalty Management Business - **Separation Announcement**: Company plans to separate into two businesses: biopharma operations and royalty management [2] - **Key Products**: - **Jemperli**: PD-1 antagonist with expected run rate of $1.4 billion to $1.5 billion; AnaptysBio anticipates substantial royalties based on sales tiers [3][4] - **Imsidolimab**: IL-36 receptor antagonist partnered with Vanda Pharmaceuticals, expected approval next year [6] Financial Overview - **Cash Position**: Expected $300 million cash at the end of the year [2] - **Royalty Structure**: Royalties range from 8% to 25% based on sales thresholds, with potential for significant revenue [4][6] Market Opportunity - **Celiac Disease**: Estimated 2 million patients in the US, with 250,000 potentially eligible for biologics by the 2030s [19] - **EOE Market**: Dupilumab, the only approved therapy, has generated $2 billion in sales, indicating a growing market for new therapies [20][23] Competitive Landscape - **Competitors**: Other companies like Novartis and Teva are also developing therapies targeting similar pathways in autoimmune diseases [9][10] - **Differentiation**: AnaptysBio's approach targets both inflammation and the underlying autoimmune response, which may provide advantages over existing therapies [15][22] Conclusion - **Future Plans**: AnaptysBio aims to advance AMV033 into further trials and move Rosnilimab into phase 3 next year, with a focus on addressing significant unmet needs in autoimmune diseases [31][32]